Literature DB >> 11827556

Apolipoprotein A-I(Milano) and apolipoprotein A-I(Paris) exhibit an antioxidant activity distinct from that of wild-type apolipoprotein A-I.

John K Bielicki1, Michael N Oda.   

Abstract

Apolipoprotein A-I(Milano) (apoA-I(Milano)) and apoA-I(Paris) are rare cysteine variants of apoA-I that produce a HDL deficiency in the absence of cardiovascular disease in humans. This paradox provides the basis for the hypothesis that the cysteine variants possess a beneficial activity not associated with wild-type apoA-I (apoA-I(WT)). In this study, a unique antioxidant activity of apoA-I(Milano) and apoA-I(Paris) is described. ApoA-I(Milano) was twice as effective as apoA-I(Paris) in preventing lipoxygenase-mediated oxidation of phospholipids, whereas apoA-I(WT) was poorly active. Antioxidant activity was observed using the monomeric form of the variants and was equally effective before and after initiation of oxidative events. ApoA-I(Milano) protected phospholipid from reactive oxygen species (ROS) generated via xanthine/xanthine oxidase (X/Xo) but failed to inhibit X/Xo-induced reduction of cytochrome c. These results indicate that apoA-I(Milano) was unable to directly quench ROS in the aqueous phase. There were no differences between lipid-free apoA-I(Milano,) apoA-I(Paris), and apoA-I(WT) in mediating the efflux of cholesterol from macrophages, indicating that the cysteine variants interacted normally with the ABCA1 efflux pathway. The results indicate that incorporation of a free thiol within an amphipathic alpha helix of apoA-I confers an antioxidant activity distinct from that of apoA-I(WT). These studies are the first to relate gain of function to rare cysteine mutations in the apoA-I primary sequence.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11827556     DOI: 10.1021/bi011716p

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  29 in total

1.  Structure/function relationships of apolipoprotein a-I mimetic peptides: implications for antiatherogenic activities of high-density lipoprotein.

Authors:  Wilissa D'Souza; John A Stonik; Andrew Murphy; Steven J Demosky; Amar A Sethi; Xiao L Moore; Jaye Chin-Dusting; Alan T Remaley; Dmitri Sviridov
Journal:  Circ Res       Date:  2010-05-27       Impact factor: 17.367

Review 2.  Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a review.

Authors:  C Roger White; David W Garber; G M Anantharamaiah
Journal:  J Lipid Res       Date:  2014-08-25       Impact factor: 5.922

Review 3.  Raising high-density lipoprotein cholesterol: innovative strategies against an old adversary.

Authors:  Dhruv Kazi; John A Farmer
Journal:  Curr Atheroscler Rep       Date:  2005-03       Impact factor: 5.113

4.  Surface rheology and adsorption kinetics reveal the relative amphiphilicity, interfacial activity, and stability of human exchangeable apolipoproteins.

Authors:  Victor Martin Bolanos-Garcia; Anne Renault; Sylvie Beaufils
Journal:  Biophys J       Date:  2007-11-09       Impact factor: 4.033

Review 5.  HDL therapy for cardiovascular diseases: the road to HDL mimetics.

Authors:  C Roger White; Geeta Datta; Zhenghao Zhang; Himanshu Gupta; David W Garber; Vinod K Mishra; Mayakonda N Palgunachari; Shaila P Handattu; Manjula Chaddha; G M Anantharamaiah
Journal:  Curr Atheroscler Rep       Date:  2008-10       Impact factor: 5.113

6.  Asymmetry in the lipid affinity of bihelical amphipathic peptides. A structural determinant for the specificity of ABCA1-dependent cholesterol efflux by peptides.

Authors:  Amar A Sethi; John A Stonik; Fairwell Thomas; Steve J Demosky; Marcelo Amar; Edward Neufeld; H Bryan Brewer; W Sean Davidson; Wilissa D'Souza; Dmitri Sviridov; Alan T Remaley
Journal:  J Biol Chem       Date:  2008-09-19       Impact factor: 5.157

Review 7.  Genetic control of apoprotein A-I and atheroprotection: some insights from inbred strains of mice.

Authors:  Godfrey S Getz; Catherine A Reardon
Journal:  Curr Opin Lipidol       Date:  2017-10       Impact factor: 4.776

8.  Bone marrow transplantation shows superior atheroprotective effects of gene therapy with apolipoprotein A-I Milano compared with wild-type apolipoprotein A-I in hyperlipidemic mice.

Authors:  Lai Wang; Behrooz G Sharifi; Theresa Pan; Lei Song; Ada Yukht; Prediman K Shah
Journal:  J Am Coll Cardiol       Date:  2006-08-28       Impact factor: 24.094

Review 9.  Recombinant high-density lipoprotein formulations.

Authors:  Esad Vucic; Robert S Rosenson
Journal:  Curr Atheroscler Rep       Date:  2011-02       Impact factor: 5.113

10.  Vasculoprotective Effects of Apolipoprotein Mimetic Peptides: An Evolving Paradigm In Hdl Therapy (Vascular Disease Prevention, In Press.).

Authors:  C Roger White; Geeta Datta; Paulina Mochon; Zhenghao Zhang; Ollie Kelly; Christine Curcio; Dale Parks; Mayakonda Palgunachari; Shaila Handattu; Himanshu Gupta; David W Garber; G M Anantharamaiah
Journal:  Vasc Dis Prev       Date:  2009-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.